# EU-1-13-878_public-assessment-report_20131025_20131025_defitelio-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
25 July 2013
EMA/CHMP/824715/2012
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Defitelio
International non-proprietary name: Defibrotide
Procedure No. EMEA/H/C/002393
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential
nature deleted.
7 Westferry Circus . Canary Wharf . London E14 4HB . United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613
E-mail info@ema.europa.eu Website www.ema.europa.eu
An agency of the European Union
Table of contents
1. Background information on the procedure
8
1.1. Submission of the dossier.
8
1.2. Manufacturers
9
1.3. Steps taken for the assessment of the product
9
1.4. Steps taken for the re-examination procedure
10
2. Scientific discussion
11
2.1. Introduction
11
2.2. Quality aspects
13
2.2.1. Introduction
13
2.2.2. Active Substance
13
2.2.3. Finished Medicinal Product
15
2.2.4. Discussion on chemical, pharmaceutical and biological aspects
17
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
17
2.2.6. Recommendation(s) for future quality development
17
2.3. Non-clinical aspects
18
2.3.1. Introduction
18
2.3.2. Pharmacology
18
2.3.3. Pharmacokinetics.
20
2.3.4. Toxicology
21
2.3.5. Ecotoxicity/environmental risk assessment
23
2.3.6. Discussion on non-clinical aspects.
24
2.4. Clinical aspects
25
2.4.1. Introduction
25
2.4.2. Pharmacokinetics
26
2.4.3. Pharmacodynamics
30
2.4.4. Discussion on clinical pharmacology
33
2.4.5. Conclusions on clinical pharmacology
33
2.5. Clinical efficacy
33
2.5.1. Dose response study(ies)
34
2.5.2. Main study(ies)
37
2.5.3. Discussion on clinical efficacy
71
2.5.4. Conclusions on the clinical efficacy.
73
2.6. Clinical safety
74
2.6.1. Discussion on clinical safety
80
2.6.2. Conclusions on the clinical safety
82
2.7. Pharmacovigilance
82
Assessment report
EMA/CHMP/824715/2012
Page 2/135
